Search Results
Results found for "GPCR Drug Design"
- First AMA of 2026: GPCR Pharmacology, Biased Signaling & Mechanistic Clarity
2026 GPCR Pharmacology AMA: Receptor Theory, Biased Signaling & Assay Interpretation The first GPCR Pharmacology Kenakin will address receptor theory, assay interpretation, biased signaling, and practical drug discovery disciplined interpretation As the archive grows, it becomes a searchable extension of Terry’s teaching — designed as new videos are released: ▶️ https://www.youtube.com/@TerryPharmacologyCorner New White Paper on GPCR School of Medicine, has authored a new white paper in collaboration with Eurofins DiscoverX: Assess GPCR
- Allosteric modulation of GPCRs: From structural insights to in silico drug discovery
of the prime targets for marketed drugs. While traditional drug discovery programs have focused on the development of ligands targeting the binding current strategies for the identification of allosteric sites as well as ligand-based and structure-based drug discovery and design." Read more at the source #DrGPCR #GPCR #IndustryNews
- GPCR Selectivity Beyond the Receptor — Live April 9th with Bryan Roth
structural biology and drug discovery at opioid and galanin receptors. Joseph Kim: Structural Biology and Drug Discovery at GPCRs Cryo-EM has transformed how we visualize receptor–ligand interactions — and with it, how we think about drug discovery at GPCRs. GPCR Dr. GPCR is the intelligence and community platform for GPCR scientists. Plus 6 industry updates and 1 new Masterclass recording now available — Purinergic GPCR Ligand Design
- Drug Discovery Pharmacology Principles That Turn Assays Into Real Medicines
But pharmacology introduces a sobering truth: A drug that cannot reach its target is not a drug. Chemists Make The Drugs Drug discovery is fundamentally a team sport . both disciplines collaborate effectively, pharmacology data becomes a roadmap that guides molecular design toward viable drug candidates. teams navigating development bottlenecks scientific leaders seeking clear pharmacological guidance GPCR
- Transmembrane domains of GPCR dimers – a novel hot spot for drug discovery
Transmembrane domains of GPCR dimers – a novel hot spot for drug discovery G-protein-coupled receptors GPCR dimers are therefore emerging drug targets in different therapeutic areas including depression, What is the potential of targeting GPCR dimer interface in drug discovery? GPCR drugs efficacy usually depends on a pathway (G protein or β-arrestin), whereas side effects are dimerization while accelerating drug discovery targeting GPCR dimers.
- How a Failed Experiment Created a Powerful GPCR Imaging Tool
Broichhagen aka JB, the goal was bold and elegant: Create a photo-switchable ligand to remotely control GPCR They had a tool that did bind the GPCR… but not in the light-controlled way they wanted. For metabolic GPCRs (like GLP-1 and GIP receptors): Drug efficacy depends on which cells express the Clarify brain vs. peripheral contributions to metabolic therapy Guide how next-generation incretin drugs are designed Support cell-targeted conjugate therapeutic strategies It didn’t just solve a problem.
- GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026
 sit at the core of drug discovery. Yet small design choices—often treated as technical details—quietly reshape the affinity you think you Design GPCR binding affinity experiments that tell the truth , ensuring affinity data support—rather in-depth lessons and 3 live AMAs  spanning binding, kinetics, efficacy, mechanism, and experimental design—built GPCR Premium Membership Gives You an Edge Premium Membership is designed for scientists and teams who
- Illuminating C5aR Biology: The Role of Fluorescent Ligands in GPCR Research
Approximately one-third of the drugs currently in clinical use are GPCR ligands. The efficiency, versatility, and convergence of our proprietary conjugation technology enabled the design Conclusions By applying our proprietary technology, we have designed and synthesized two optimal fluorescent Trends in GPCR Drug Discovery: New Agents, Targets and Indications. Nature Reviews Drug Discovery 2017 , 16 (12), 829–842. https://doi.org/10.1038/nrd.2017.178 . (2) Dumitru
- How Fast Does a Drug Work?
Kenakin’s latest  lecture delivers exclusive, real-world insight designed to equip you to move beyond surface-level affinity data and make faster, more confident decisions in your drug discovery pipeline In this session, you’ll gain: ✅ A practical framework for understanding when a drug’s rate of binding truly reflects equilibrium—and when it doesn’t This is practical kinetic expertise—crafted to help drug s Corner  ______ #DrugDiscovery #Pharmacology #DrugKinetics #PipelineEfficiency #PharmaInnovation #GPCR
- GPCR Agonist-to-Antagonist Conversion: Enabling the Design of Nucleoside Functional Switches for...
October 2022 GPCR Agonist-to-Antagonist Conversion: Enabling the Design of Nucleoside Functional Switches This approach can expand the repertoire of adenosine receptor antagonists that can be designed based Read more at the source #DrGPCR #GPCR #IndustryNews
- Inside the New Dr. GPCR Ecosystem: Learning, Insight, and Momentum for 2026
After a brief pause over the holidays and last month, we’re back in full force—designed to help you make Targeted Drug Discovery Summit, Boston. fundamentals while keeping pace with modern GPCR research and drug discovery. GPCR Podcast—GPCR Assay Strategy, Bias, and Translational Drug Discovery In this episode of the Dr. GPCR Premium is designed for scientists and teams who can’t afford to chase every headline—or miss the
- How Collaboration Drives GPCR Discoveries
was a set of chemical probes that finally allowed researchers to visualize where receptors exist, how drugs Why GPCR Collaboration Is Essential for Modern Science Hodson makes the point bluntly: modern GPCR science Together, they push GPCR science faster. It will hinge on the teams who can map GPCR signaling with precision and design therapies that fit real pathways Creating chemical tools that finally show how drugs reach their targets These aren’t solo-lab
- Quantifying Receptor Selectivity in Modern Drug Discovery
Selectivity is one of the most overused—and misunderstood—terms in drug discovery. Without full curves, you cannot separate drug properties from detection limitations. In a world of increasingly complex GPCR modulation, these distinctions are not academic. It is designed for: Pharmacologists sharpening foundational tools Discovery teams solving assay bottlenecks Leaders making mechanism-driven portfolio decisions GPCR innovation is accelerating.
- Exciting GPCR Events for Next Year! + GPCR Weekly Rocket Launch ⦿ Oct 28 - Nov 3, 2024
Nasdaq debutante Septerna swells its IPO to $331m Nxera Pharma and Antiverse Enter Collaboration To Design Therapeutics, Inc. has received Orphan Drug Designation (ODD) from the FDA for its hematopoietic stem Drugs like Ozempic will change the world GPCR Events, Meetings, and Webinars November 5 - 7, 2024 | 16th Forum Conference November 26 - 28, 2024 | GPCRs-Targeted Drug Discovery Summit Europe NEW December of Advanced Multimodal Approaches to GPCR Drug Discovery NEW March 12 - 14, 2025 | NextGen Biomed 2025
- Extracellular signal-regulated kinases – a potential pathway for GPCR-targeted drug discovery
Notably, G-protein-coupled receptors (GPCRs), representing the biggest drug target, have been revealed Historically, drug discovery efforts targeting GPCRs focused on G-protein-dependent signaling pathways drug discovery (Eishingdrelo & Kongsamut, 2013). Minireview: targeting GPCR activated ERK pathways for drug discovery. Biased receptor signaling in drug discovery. Pharmacological Reviews, 71(2), 267-315.
- From Pipettes to Platforms: The Evolution of GPCR Research
— a transformation that reshaped how scientists design experiments and interpret signaling. The field moved from single readouts to integrated signaling landscapes, accelerating drug discovery Today, success depends less on manual precision and more on experimental design, data interpretation, What started as hand-built assays on ice has become integrated platforms for drug discovery, systems GPCR Podcast 🔓 Get tools, deep dives, and exclusive insights with  Dr. GPCR Premium .
- How Schild Analysis Protects Your Conclusions in GPCR Research
Why this matters Receptor distribution shapes incretin hormone drug effects across islets and neural Sparked a Scientific Journey Molecular Creativity in Drug Discovery Why Dr. publications, events, insights, and opportunities designed to support your career, your lab, or your Aside from his vast experience in drug development, not to mention his extensive publication record, GPCR Team
- How GPCR Collaboration Built an Innovation Engine
Rather than carving out turf, they grew by designing around collective capacity . techniques, not just one pipeline Senior scientists embedded as “connectors” between programs This design It was designed. Weekly seminars were mandatory but lightweight, designed to connect  rather than perform. This ecosystem design blueprint applies to biotech teams and academic consortia alike.
- Pharmacologic Models
Are you ready to truly understand how pharmacologists predict whole-body drug response from a single Probability Models  This is practical drug development expertise from Terry’s 40+ years of experience GPCR News.  Elevate your pharmacology expertise. Unlock "Pharmacologic Models" now
- Fluorescence based HTS compatible ligand binding assays for dopamine D3 receptors in baculovirus preparations and live cells
depression, schizophrenia and Parkinson’s disease. [1,2] Several dopamine ligands have been approved as drugs Altogether, these aspects hint that the linker design and strategy can provide options for the tuning Current Drug Treatments Targeting Dopamine D3 Receptor. Structure-Based Design of High-Affinity Fluorescent Probes for the Neuropeptide Y Y1 Receptor. J. An Order of Magnitude Faster DNA-PAINT Imaging by Optimized Sequence Design and Buffer Conditions.
- Beyond HEK293 — Terry Hébert on iPSC-Derived GPCR Models, Live April 16,
April 29, and the GPCRs Drug Discovery Summit April 28-30. iPSC-Derived GPCR Models: Beyond HEK293 for producing a fundamentally different pharmacological pattern — with different consequences for assay design allosteric binding modes, and why establishing that distinction early carries immense practical value for drug GPCR at the GPCRs Targeted Drug Discovery Summit — Boston, April 28-30 The GPCRs Targeted Drug Discovery GPCR University Learner About Dr. GPCR Dr.
- How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs
Eric Trinquet, a veteran innovator behind functional GPCR assays like HTRF and IP-One, believes rigid If you’re building tools or careers in GPCR science, this is your playbook. It began with an unmet need: how to track Gq-coupled GPCR activity without the mess of calcium flux or GPCR  Dr. GPCR X Revvity Collaboration ⸻ Want more like this? 👉 Join the Dr. GPCR Premium Ecosystem  for behind-the-scenes access to GPCR innovators, exclusive deep-dives, and practical
- Dr. GPCR Spotlights Revvity’s pHSense™ Internalization Tools
GPCR Ecosystem. A GPCR Internalization Tool Designed for Real Research Needs Built on more than two decade A GPCR Internalization Tool Designed for Real Research Needs s of GPCR assay innovation , pHSense™  was developed to overcome GPCR. GPCR Dr.
- Beyond Clearance: The Strategic Power of Irreversible Drug Binding
It’s a design space , not a binary choice, and penetration is just the beginning. Designing Strategically with Irreversible Drug Binding in Mind When irreversible mechanisms are designed but designing with them . 👉 Unlock Irreversible Drugs —  Only in Terry’s Corner! design. Kenakin with your own enzyme or GPCR interaction puzzles.
- A Note from Yamina: Building the Next Chapter of Dr. GPCR
GPCR. Dear Dr. GPCR, it was with a simple goal: to connect people who shared a passion for GPCR science and discovery GPCR Foundry  — our R&D and biotech hub designed to bridge GPCR science with execution. The Dr. GPCR Retreat  — our largest in-person event yet, designed to bring together scientists, industry leaders GPCR About Dr. GPCR Dr.
- Are You Guessing or Forecasting? Master GPCR Pharmacologic Models Before It’s Too Late
🔹 Elevate your strategy → Building clarity in GPCR drug discovery Even the strongest GPCR programs GPCR University Learner Dr. GPCR Podcast - Surviving Discovery’s Gauntlet Dr. Find your edge:  Dodge the traps that derail real drug discovery careers.  Listen Now – Real Lessons from a GPCR Expert ➤ The future of GPCR isn’t waiting. GPCR Team Read Full Edition ➤
- Posttranslational modifications in GPCR internalization
as the most important drug targets. Classically, GPCR internalization has been considered to lead to receptor desensitization. new understanding for the receptor internalization, the mechanism of physiology/pathology and novel drug , which will offer new insights into the regulatory mechanism of GPCR signaling and novel drug targets Read more at the source #DrGPCR #GPCR #IndustryNews
- Enhancing GPCR Research Outreach | Dr GPCR University early-bird registration ends soon!
with real-time kinetics Discovering new ligands and GPCR behaviors for unique drug profiles  GPCR Event Logo Contest : Let your creativity shine by submitting your design for the Logo Contest before August relaxation of airway smooth muscle GPCR Binders, Drugs, and more Expanding Structure-Activity Relationships breathe new life into schizophrenia pipeline GPCR Dynamics Reveal Mechanisms for Drug Discovery DMS: in drug discovery October 2024 | Biologics US 2024  October 2 - 4, 2024 | 9th GPCRs in Medicinal Chemistry
- How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology
It would later shape how he designed fluorescent probes, how he evaluated biological constraints, and The project required designing peptide–fluorophore conjugates that would bind GLP-1R with high specificity Designing Reliable GPCR Imaging Tools for Real Biological Systems Success brought new challenges. This strategy accelerated discovery and reduced noise, helping them understand how each design change with high precision, in any tissue, across multiple colors, with tools designed as much by computation
- Mechanism vs. Assumption: A Model-First Path to Getting GPCR MoA Right
this week:  5-MeO-DMT: the "God Molecule"; Novo Nordisk looks to next generation of obesity, diabetes drugs Upcoming events:  “Drug Discovery at Superluminal Speeds”; and Discovery on Target 2025—GPCR track you replace inference with models that disentangle mechanism—so your next go/no-go, dose range, and assay design ) is set to be a high-signal GPCR forum—bridging biased signaling, allostery, and structure-guided design Attendee Ready to turn ambiguous signals into confident, defensible decisions—and join a community designed

























